MLTX FINAL DEADLINE ALERT: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misled investors by asserting that the unique Nanobody structure of sonelokimab would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved BIMZELX [3]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy, MoonLake's stock plummeted from $61.99 to $6.24, representing a 90% loss [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore legal options and the possibility of becoming the Lead Plaintiff [5].